Journals / Klimik Dergisi / 2015 / Cilt: 28 - Sayı: 2

Infective Endocarditis: An Update

İnfektif Endokardit: Güncel Bilgiler

Pages
46–67
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, epidemiology, etiology, diagnosis and prevention of IE in Turkey and other parts of the world were discussed in the light of current guidelines and recent research; and some recommendations were made to improve the management of IE.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although infective endocarditis (IE) has been recognized for years and despite the advances in the diagnosis and treatment, it is associated with a mortality rate as high as 20% even in developed countries in which IE cases have more access to new diagnostic technologies and surgical facilities.
📊
Key Findings & Data:The mortality rate is even higher in Turkey and is reported to be 30%.
💡
Conclusion & Impact:In this review, epidemiology, etiology, diagnosis and prevention of IE in Turkey and other parts of the world were discussed in the light of current guidelines and recent research; and some recommendations were made to improve the management of IE.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Although infective endocarditis (IE) has been recognized for years and despite the advances in the diagnosis and treatment, it is associated with a mortality rate as high as 20% even in developed countries in which IE cases have more access to new diagnostic technologies and surgical facilities. The mortality rate is even higher in Turkey and is reported to be 30%. There are many guidelines on the management of IE, but compliance with these guidelines is poor in daily clinical practice. A standardised strategy based on a local consensus of IE among infectious diseases and clinical microbiology specialists, cardiologists and cardiac surgeons (i.e., infective endocarditis team) can result in reproducibility of treatment for all patients regardless of the attending physician. In this review, epidemiology, etiology, diagnosis and prevention of IE in Turkey and other parts of the world were discussed in the light of current guidelines and recent research; and some recommendations were made to improve the management of IE.

Özet

İnfektif endokardit (İE), çok uzun yıllardan beri bilinen bir has-Although infective endocarditis (IE) has been recognized for talık olmasına ve tanı ve tedavisinde birçok gelişmeler sağlanyears and despite the advances in the diagnosis and treatment, masına karşın, tüm tıbbi olanaklara erişimin mümkün olduğu it is associated with a mortality rate as high as 20% even in gelişmiş ülkelerde bile %20 gibi yüksek bir mortalite hızı sergiler. developed countries in which IE cases have more access to new Ülkemizde ise bu hız %30'u bulmaktadır. İE'nin tanısı, tedavisi diagnostic technologies and surgical facilities. The mortality ve önlenmesi konusunda yayımlanmış çok fazla sayıda rehber rate is even higher in Turkey and is reported to be 30%. There vardır. Ancak günlük klinik pratikte, bu rehberlere uyum konu-are many guidelines on the management of IE, but compliance sunda önemli sorunlar yaşanmakta, bu da hasta prognozunu with these guidelines is poor in daily clinical practice. A stanolumsuz yönde etkilemektedir. İE'li hastaların tanı ve tedavisi dardised strategy based on a local consensus of IE among iniçin infeksiyon hastalıkları ve klinik mikrobiyoloji, kardiyoloji ve fectious diseases and clinical microbiology specialists, cardiolokardiyovasküler cerrahi uzmanlarının birlikte çalışması (İE ekibi) gists and cardiac surgeons (i.e., infective endocarditis team) can ve ortak bir yaklaşım oluşturması, başvurulan hekimden bağımresult in reproducibility of treatment for all patients regardless sız olarak, her hastaya standard bir tedavi uygulanmasını sağla-of the attending physician. In this review, epidemiology, etiolyabilir. Bu derlemede, İE epidemiyolojisi, etkenleri, tanısı, tedaogy, diagnosis and prevention of IE in Turkey and other parts visi ve önlenmesi konusunda ülkemizde ve dünyadaki mevcut of the world were discussed in the light of current guidelines durum, güncel yayınlar ve rehberler eşliğinde değerlendirilmiş, and recent research; and some recommendations were made İE'li hasta bakımının daha iyi hale getirilebilmesi için öneriler to improve the management of IE.sunulmuştur.

🔖

Cite This Article

ŞİMŞEK, S. Y. (2022). Infective Endocarditis: An Update. Klimik Dergisi, Cilt: 28 - Sayı: 2, 46–67. https://ajindex.com/articles/573617

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Fowler VG, Scheld WM, Bayer AS. Endocarditis and intravascular infections. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Doug- las, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia: Elsevier Saunders, 2015: 990-1028.
  2. Starkebaum V, Durack D, Beeson P. The "incubation period" of su- bacute bacterial endocarditis. Yale J Biol Med. 1977; 50(1): 49-58.
  3. Issa VS, Fabri J Jr, Pomerantzeff PM, Grinberg M, Pereira-Barreto AC, Mansur AJ. Duration of symptoms in patients with infective endocarditis. Int J Cardiol. 2003; 89(1): 63-70. [CrossRef] Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbio- logy and Infectious Diseases (ESCMID) and the International So- ciety of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J. 2009; 30(19): 2369-413. [CrossRef] Ben-Ami R, Giladi M, Carmeli Y, Orni-Wasserlauf R, Siegman-Igra Y. Hospital-acquired infective endocarditis: should the definition be broadened? Clin Infect Dis. 2004; 38(6): 843-50. [CrossRef] Hoen B, Duval X. Clinical practice. Infective endocarditis. N Eng J Med. 2012; 368(15): 1425-33. [CrossRef] Thuny F, Grisoli D, Collart F, Habib G, Raoult D. Management of infective endocarditis: challenges and perspectives. Lancet. 2012; 379(9819): 965-75. [CrossRef] Murdoch, DR, Corey GR, Hoen B, et al. Clinical presentation, eti- ology, and outcome of infective endocarditis in the 21st Century. The International Collaboration on Endocarditis-Prospective Co- hort Study. Arch Intern Med. 2009; 169(5): 463-73. [CrossRef] Selton-Suty C, Célard M, Le Moing V, et al. Preeminence of Staph- ylococcus aureus in infective endocarditis: a 1-year population- based survey. Clin Infect Dis. 2012; 54(9): 1230-9. [CrossRef] Çetinkaya Y, Akova M, Akalın HE, et al. A retrospective review of 228 episodes of infective endocarditis where rheumotic valvular disease still common. Int J Antimicrob Agents. 2001; 18(1): 1-7. [CrossRef] Leblebicioğlu H, Yılmaz H, Taşova Y, et al. Characteristics and analysis of risk factors for mortality in infective endocarditis. Eur J Epidemiol. 2006; 21(1): 25-31. [CrossRef] Tuğcu A, Yıldırımtürk Ö, Baytaroğlu C, et al. Clinical spectrum, presentation, and risk factors for mortality in infective endocar- ditis: